Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions for Clinical Practice

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 7, 2009, Pages

  Arora, Gaurav ^a   Singh, Gurkirpal ^a,b   Triadafilopoulos, George ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Institute of Clinical Outcomes Research and Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CLOPIDOGREL; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDOMETACIN; KETOPROFEN; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PIROXICAM; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE; TENOXICAM;

ARTHRITIS; CARDIOVASCULAR DISEASE; CHRONIC ARTHRITIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DUODENUM ULCER; DYSPEPSIA; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HUMAN; LOW DRUG DOSE; MONOTHERAPY; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STOMACH PROTECTION; STOMACH ULCER; UPPER GASTROINTESTINAL BLEEDING;

EID: 67649313312     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.03.015     Document Type: Review

References (107)

1. Lee M., and Feldman M. The aging stomach: implications for NSAID gastropathy. Gut 41 (1997) 425-426
2. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
3. Case J.P., Baliunas A.J., and Block J.A. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 163 (2003) 169-178
4. Pincus T., Koch G., Lei H., et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 63 (2004) 931-939
5. Pincus T., Koch G.G., Sokka T., et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 44 (2001) 1587-1598
6. Fries J.F., Miller S.R., Spitz P.W., et al. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 20 Suppl (1990) 12-19
7. Smalley W.E., Griffin M.R., Fought R.L., et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J Gen Intern Med 11 (1996) 461-469
8. Stalnikowicz R., and Rachmilewitz D. NSAID-induced gastroduodenal damage: is prevention needed?. A review and metaanalysis. J Clin Gastroenterol 17 (1993) 238-243
9. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
10. Micklewright R., Lane S., Linley W., et al. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. Aliment Pharmacol Ther 17 (2003) 321-332
11. Gabriel S.E., Jaakkimainen L., and Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 115 (1991) 787-796
12. Garcia Rodriguez L.A., and Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 769-772
13. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114 (1991) 257-263
14. Henry D., Lim L.L., Garcia Rodriguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 312 (1996) 1563-1566
15. Langman M.J., Weil J., Wainwright P., et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343 (1994) 1075-1078
16. Silverstein F.E., Graham D.Y., Senior J.R., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
17. Singh G., Ramey D.R., Morfeld D., et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 156 (1996) 1530-1536
18. Hernandez-Diaz S., and Rodriguez L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160 (2000) 2093-2099
19. Chan F.K. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf 28 (2005) 287-300
20. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
21. Goldstein J.L., and Fort J.G. Incidence of endoscopic gastroduodenal ulcers in subjects on 325 mg qd of aspirin for cardiovascular prophylaxis with placebo, a COX-2 specific inhibitor, or a nonspecific NSAID: results from a randomized, double-blind, controlled trial. GA. American College of Rheumatology Annual Meeting [Poster LB14/523] (23-28 October, 2003) Orlando, FL
22. Wilcox C.M., Shalek K.A., and Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med 154 (1994) 42-46
23. Niv Y., Battler A., Abuksis G., et al. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci 50 (2005) 78-80
24. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321 (2000) 1183-1187
25. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
26. McQuaid K.R., and Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119 (2006) 624-638
27. Labenz J., Petersen K.U., Rosch W., et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 17 (2003) 1015-1019
28. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev (2002) CD002296
29. Ekström P., Carling L., Wetterhus S., et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol 31 (1996) 753-758
30. Cullen D., Bardhan K.D., Eisner M., et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 12 (1998) 135-140
31. Bianchi Porro G., Lazzaroni M., Petrillo M., et al. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment: a double blind placebo controlled study. Ital J Gastroenterol Hepatol 30 (1998) 43-47
32. Bianchi Porro G., Lazzaroni M., Imbesi V., et al. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. Dig Liver Dis 32 (2000) 201-208
33. Pilotto A., Di Mario F., Franceschi M., et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 14 (2000) 1077-1082
34. Stupnicki T., Dietrich K., Gonzalez-Carro P., et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 68 (2003) 198-208
35. Scheiman J.M., Yeomans N.D., Talley N.J., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101 (2006) 701-710
36. Regula J., Butruk E., Dekkers C.P., et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 101 (2006) 1747-1755
37. Yeomans N., Lanas A., Labenz J., et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103 (2008) 2465-2473
38. Pilotto A., Franceschi M., Leandro G., et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 20 (2004) 1091-1097
39. Vonkeman H.E., Fernandes R.W., van der Palen J., et al. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther 9 (2007) R52
40. Hawkey C.J., Karrasch J.A., Szczepanski L., et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338 (1998) 727-734
41. Yeomans N.D., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs: Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338 (1998) 719-726
42. Graham D.Y., Agrawal N.M., Campbell D.R., et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162 (2002) 169-175
43. Olteanu D., Balan C., Andronescu A., et al. Efficacy of pantoprazole as compared to omeprazole and misoprostol in NSAID associated gastric ulcer. Gut 47 Suppl III (2000) A82
44. Kujundzic M., Ljubicic N., Banic M., et al. The frequency of relapse and bleeding of previous gastroduodenal lesions in NSAID-users on maintenance treatment. Gut 47 Suppl III (2000) A84
45. Jensen D., Ho S., Hamamah S., et al. A randomized study of omeprazole compared to misoprostol for prevention of recurrent ulcers and ulcer hemorrhage in high risk patients ingesting aspirin or NSAIDS. Gastroenterology 118 (2000) A892
46. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
47. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515
48. Ray W.A., Chung C.P., Stein C.M., et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 133 (2007) 790-798
49. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 127 (2004) 1038-1043
50. Lai K.C., Chu K.M., Hui W.M., et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118 (2005) 1271-1278
51. CONDOR: Celecoxib vs. Omeprazole and Diclofenac for at-risk Osteoarthritis and Rheumatoid arthritis patients. ClinicalTrials.gov Identifier: NCT00141102. http://clinicaltrials.gov/show/NCT00141102 Accessed January 7, 2008
52. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 (2007) 1621-1626
53. Hawkey C., Talley N.J., Yeomans N.D., et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 100 (2005) 1028-1036
54. van Leen M.W., van der Eijk I., and Schols J.M. Prevention of NSAID gastropathy in elderly patients: an observational study in general practice and nursing homes. Age Ageing 36 (2007) 414-418
55. Spiegel B.M., Farid M., Dulai G.S., et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med 119 448 (2006) 427-436
56. Ibanez L., Vidal X., Vendrell L., et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 23 (2006) 235-242
57. van Hecken A., Depre M., Wynants K., et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact 14 (1998) 193-205
58. Delaney J.A., Opatrny L., Brophy J.M., et al. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 177 (2007) 347-351
59. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
60. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
61. Lai K.C., Chu K.M., Hui W.M., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 4 (2006) 860-865
62. Ng F.H., Wong B.C., Wong S.Y., et al. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk: a single-blind, randomized controlled study. Aliment Pharmacol Ther 19 (2004) 359-365
63. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
64. American College of Cardiology (ACC)/American College of Gastroenterology (ACG)/American Heart Association (AHA) joint comment on studies regarding possible interaction of clopidogrel and proton pump inhibitors. http://www.cardiosource.com/documents/PPI_Statement.pdf Accessed December 20, 2008
65. Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1). http://clinicaltrials.gov/ct2/show/NCT00557921 Accessed February 17, 2008
66. Bardhan K.D., Ahlberg J., Hislop W.S., et al. Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 8 (1994) 215-220
67. Agrawal N.M., Campbell D.R., Safdi M.A., et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study-NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 160 (2000) 1455-1461
68. Bianchi Porro G., Lazzaroni M., Manzionna G., et al. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther 12 (1998) 355-360
69. Massimo Claar G., Monaco S., Del Veccho Blanco C., et al. Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 12 (1998) 463-468
70. Goldstein J.L., Johanson J.F., Hawkey C.J., et al. Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy: a randomized study comparing ranitidine with esomeprazole. Aliment Pharmacol Ther 26 (2007) 1101-1111
71. Goldstein J.L., Johanson J.F., Suchower L.J., et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 100 (2005) 2650-2657
72. Yeomans N.D., Svedberg L.E., and Naesdal J. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?. Int J Clin Pract 60 (2006) 1401-1407
73. Lanza F.L. A guideline for the treatment and prevention of NSAID-induced ulcers: members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93 (1998) 2037-2046
74. Lanas A., Perez-Aisa M.A., Feu F., et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 100 (2005) 1685-1693
75. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study-a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
76. Chan F.K., Hung L.C., Suen B.Y., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347 (2002) 2104-2110
77. Piper J.M., Ray W.A., Daugherty J.R., et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114 (1991) 735-740
78. Richy F., Bruyere O., Ethgen O., et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63 (2004) 759-766
79. Agrawal N.M., van Kerckhove H., Erhardt L.J., et al. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: a one year study. Dig Dis Sci 40 (1995) 1125-1131
80. Chan F.K.L., Sung J.J.Y., Ching J.Y.L., et al. Randomized trial of low-dose misoprostol and naproxen vs nabumetone to prevent recurrent upper gastrointestinal haemorrhage in users of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 15 (2001) 19-24
81. Raskin J.B., White R.H., Jackson J.E., et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 123 (1995) 344-350
82. Ehsanullah R.S., Page M.C., Tildesley G., et al. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 297 (1988) 1017-1021
83. Levine L.R., Cloud M.L., and Enas N.H. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 153 (1993) 2449-2454
84. Simon B., and Muller P. Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients. Scand J Gastroenterol 206 (1994) 25-28
85. Swift G.L., Heneghan M., Williams G.T., et al. Effect of ranitidine on gastroduodenal mucosal damage in patients on long-term non-steroidal anti-inflammatory drugs. Digestion 44 (1989) 86-94
86. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334 (1996) 1435-1439
87. Saini S.D., Schoenfeld P., Fendrick A.M., et al. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. Arch Intern Med 168 (2008) 1684-1690
88. Brown T.J., Hooper L., Elliott R.A., et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 10 (2006) iii-iv, xi-xiii, 1-183
89. Spiegel B.M., Chiou C.F., and Ofman J.J. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum 53 (2005) 185-197
90. Hur C., Chan A.T., Tramontano A.C., et al. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs. Ann Pharmacother 40 (2006) 1052-1063
91. Yun H.R., and Bae S.C. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Rheumatol Int 25 (2005) 9-14
92. Forgacs I., and Loganayagam A. Overprescribing proton pump inhibitors. BMJ 336 (2008) 2-3
93. Cheer S.M., Prakash A., Faulds D., et al. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 63 (2003) 101-133
94. Hahn E., Erlangen H., Bosseckert J., et al. Tolerability and safety profile of pantoprazole based on 100,134 patients: results of a German post-marketing surveillance (PMS) program. Gastroenterology 112 Suppl 4 (1997) A138
95. Lew E.A. Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 13 Suppl 5 (1999) 11-16
96. Radhofer-Welte S. Pharmacokinetics and metabolism of the proton pump inhibitor pantoprazole in man. Drugs Today (Barc) 35 (1999) 765-772
97. Dial S., Alrasadi K., Manoukian C., et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 171 (2004) 33-38
98. Akhtar A.J., and Shaheen M. Increasing incidence of Clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. J Natl Med Assoc 99 (2007) 500-504
99. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294 (2005) 2989-2995
100. Beaulieu M., Williamson D., Pichette G., et al. Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. Infect Control Hosp Epidemiol 28 (2007) 1305-1307
101. Garcia Rodriguez L.A., Ruigomez A., and Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 5 (2007) 1418-1423
102. Kaye J.A., and Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28 (2008) 951-959
103. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292 (2004) 1955-1960
104. Sarkar M., Hennessy S., and Yang Y.X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 149 (2008) 391-398
105. van Soest E.M., Sturkenboom M.C., Dieleman J.P., et al. Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther 26 (2007) 265-275
106. Study to evaluate the incidence of gastric ulcers following administration of either PN 200 or naproxen in subjects who are at risk for developing NSAID-associated ulcers. ClinicalTrials.gov Identifier: NCT00367211. http://clinicaltrials.gov/ct2/show/NCT00367211 Accessed February 17, 2008
107. Efficacy and safety study of HZT-501 (ibuprofen/famotidine) in reducing the risk of ibuprofen-associated ulcers. http://clinicaltrials.gov/ct2/show/NCT00450658 Accessed February 17, 2008